Notable ETF Outflow Detected - LABU, FDMT, ETNB, ACAD
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2024
0mins
Source: NASDAQ.COM
- LABU Stock Analysis: LABU's 52-week range is $48.402 to $176.9899 per share, with the last trade at $113.19. Comparing the share price to the 200-day moving average is a useful technical analysis technique.
- ETF Trading: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell "units." These units can be traded back and forth or created/destroyed based on investor demand. Monitoring changes in shares outstanding data helps track notable inflows and outflows in ETFs.
- Impact of Inflows and Outflows: Creation of new units in ETFs requires purchasing underlying holdings, while destruction of units involves selling these holdings. Large flows can impact the individual components held within ETFs.
- Notable Outflows: The article mentions 9 other ETFs that experienced notable outflows, providing further insights into market trends and investor behavior.
- Disclaimer: The views and opinions expressed in the article are those of the author and may not necessarily reflect those of Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FDMT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FDMT
Wall Street analysts forecast FDMT stock price to rise
6 Analyst Rating
5 Buy
0 Hold
1 Sell
Moderate Buy
Current: 12.720
Low
17.00
Averages
29.40
High
38.00
Current: 12.720
Low
17.00
Averages
29.40
High
38.00
About FDMT
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vivani Medical Appoints August Moretti to Board of Directors
- New Board Member: Vivani Medical has appointed August Moretti to its board, whose extensive experience across all phases of company growth will be instrumental in advancing the clinical development of NPM-139.
- Technology-Driven Development: Moretti will serve as chair of the Audit Committee and a member of the Compensation Committee, and his financial expertise is expected to enhance the company's utilization of its NanoPortal™ technology to address chronic diseases.
- Board Transition: Concurrently, Dr. Dean Baker announced his retirement, concluding a distinguished tenure during which he provided critical guidance during the merger, leaving a lasting impact on the company.
- Market Outlook: Vivani is developing GLP-1 based drug implants aimed at improving patient adherence to medication, which is expected to positively affect patients with obesity and type-2 diabetes.
See More
Vivani Medical Appoints August Moretti to Board of Directors
- New Board Member: Vivani Medical has appointed August Moretti to its board, whose extensive experience across all phases of company growth will be instrumental in advancing the clinical development of NPM-139 and leveraging NanoPortal™ technology.
- Board Transition: Concurrently, Dr. Dean Baker announced his retirement, concluding a distinguished tenure during which he provided critical guidance for the company's merger, reflecting the company's ongoing adaptability and leadership evolution.
- Technological Development Strategy: Vivani is leveraging its proprietary NanoPortal™ technology to develop ultra-long-acting drug implants aimed at addressing medication adherence issues for chronic disease patients, which is expected to significantly enhance patient treatment experiences.
- Market Potential: The company is developing GLP-1 based implants to tackle metabolic diseases, including obesity and type-2 diabetes, which are anticipated to provide patients with more stable drug delivery, thereby enhancing market competitiveness.
See More
4D Molecular Therapeutics Grants Restricted Stock Units to New Employees
- Employee Incentive Program: On June 9, 2026, 4D Molecular Therapeutics granted 66,900 Restricted Stock Units (RSUs) to seven new non-executive employees, aiming to attract talent under the 2025 Employment Inducement Award Plan, thereby enhancing the company's workforce and competitive edge.
- Product Development Progress: The lead product candidate, 4D-150, is currently in Phase 3 trials, designed to provide multi-year sustained delivery of anti-VEGF drugs through a single safe intravitreal injection, significantly reducing the treatment burden for patients with wet age-related macular degeneration, which could have a profound impact on patient care.
- Gene Therapy Innovation: 4D-710 is the first known genetic medicine to successfully deliver and express the CFTR transgene in the lungs of cystic fibrosis patients via aerosol delivery, marking a significant breakthrough in gene therapy and potentially offering new treatment options for this patient population.
- Clinical Development Status: All product candidates are in clinical or preclinical development and have not yet received approval from the U.S. Food and Drug Administration or other regulatory authorities, highlighting the company's cutting-edge exploration in biotechnology and potential market opportunities.
See More
4D Molecular Therapeutics Q1 Earnings Beat Expectations
- Earnings Report: 4D Molecular Therapeutics reported a Q1 GAAP EPS of -$1.01, missing expectations by $0.07, indicating ongoing challenges in profitability.
- Revenue Surge: The company achieved $3.04 million in revenue for Q1, reflecting a staggering 30,300% year-over-year increase, surpassing market expectations by $0.45 million, suggesting a significant uptick in product demand that could lay the groundwork for future growth.
- Market Reaction: Despite the EPS miss, the robust revenue growth may bolster investor confidence in the company's future prospects, particularly in the increasingly competitive biotechnology sector.
- Industry Conference Participation: 4D Molecular Therapeutics presented at the Barclays 28th Annual Global Healthcare Conference and TD Cowen's 46th Annual Healthcare Conference, enhancing its visibility and investor relations within the industry.
See More
4D Molecular Therapeutics Grants 67,600 RSUs to New Employees
- Employee Incentive Program: On April 14, 2026, 4D Molecular Therapeutics granted 67,600 Restricted Stock Units (RSUs) to five new non-executive employees, reflecting the company's commitment to attracting talent and enhancing employee motivation.
- Equity Grant Context: The RSUs were awarded under the Company's 2025 Employment Inducement Award Plan, in compliance with Rule 5635(c)(4) of The Nasdaq Global Market, aimed at fostering a sense of belonging and increasing employee engagement through equity incentives.
- Product Development Progress: The lead product candidate, 4D-150, is currently in Phase 3 clinical trials, designed to provide multi-year sustained delivery of anti-VEGF through a single, safe intravitreal injection, significantly reducing the treatment burden associated with current methods, indicating potential market disruption.
- Future Outlook: The second product candidate, 4D-710, is the first known genetic medicine to successfully deliver and express the CFTR transgene in the lungs of cystic fibrosis patients, showcasing the company's innovative potential in gene therapy and offering new treatment options for patients.
See More
4D Molecular Therapeutics Reports 2025 Financial Highlights
- Revenue Growth: In 2025, 4D Molecular Therapeutics reported collaboration and license revenue of $85 million, primarily driven by an upfront payment from its strategic partnership with Otsuka Pharmaceutical, indicating positive commercial progress.
- Narrowed Net Loss: The company recorded a net loss of $140 million for 2025, an improvement from $161 million in 2024, reflecting enhanced operational efficiency despite increased R&D spending.
- Clinical Trial Advancements: The 4FRONT-1 Phase 3 trial for 4D-150 in wet age-related macular degeneration (AMD) completed enrollment ahead of schedule, with topline data expected in the first half of 2027, marking rapid progress in critical therapeutic areas.
- Financial Stability: As of December 31, 2025, the company had $514 million in cash, cash equivalents, and marketable securities, bolstered by $118 million in financing, ensuring a cash runway extending into the second half of 2028.
See More
Vivani Medical Appoints August Moretti to Board of Directors
- New Board Member: Vivani Medical has appointed August Moretti to its board, whose extensive experience across all phases of company growth will be instrumental in advancing the clinical development of NPM-139.
- Technology-Driven Development: Moretti will serve as chair of the Audit Committee and a member of the Compensation Committee, and his financial expertise is expected to enhance the company's utilization of its NanoPortal™ technology to address chronic diseases.
- Board Transition: Concurrently, Dr. Dean Baker announced his retirement, concluding a distinguished tenure during which he provided critical guidance during the merger, leaving a lasting impact on the company.
- Market Outlook: Vivani is developing GLP-1 based drug implants aimed at improving patient adherence to medication, which is expected to positively affect patients with obesity and type-2 diabetes.
See More
Vivani Medical Appoints August Moretti to Board of Directors
- New Board Member: Vivani Medical has appointed August Moretti to its board, whose extensive experience across all phases of company growth will be instrumental in advancing the clinical development of NPM-139 and leveraging NanoPortal™ technology.
- Board Transition: Concurrently, Dr. Dean Baker announced his retirement, concluding a distinguished tenure during which he provided critical guidance for the company's merger, reflecting the company's ongoing adaptability and leadership evolution.
- Technological Development Strategy: Vivani is leveraging its proprietary NanoPortal™ technology to develop ultra-long-acting drug implants aimed at addressing medication adherence issues for chronic disease patients, which is expected to significantly enhance patient treatment experiences.
- Market Potential: The company is developing GLP-1 based implants to tackle metabolic diseases, including obesity and type-2 diabetes, which are anticipated to provide patients with more stable drug delivery, thereby enhancing market competitiveness.
See More
4D Molecular Therapeutics Grants Restricted Stock Units to New Employees
- Employee Incentive Program: On June 9, 2026, 4D Molecular Therapeutics granted 66,900 Restricted Stock Units (RSUs) to seven new non-executive employees, aiming to attract talent under the 2025 Employment Inducement Award Plan, thereby enhancing the company's workforce and competitive edge.
- Product Development Progress: The lead product candidate, 4D-150, is currently in Phase 3 trials, designed to provide multi-year sustained delivery of anti-VEGF drugs through a single safe intravitreal injection, significantly reducing the treatment burden for patients with wet age-related macular degeneration, which could have a profound impact on patient care.
- Gene Therapy Innovation: 4D-710 is the first known genetic medicine to successfully deliver and express the CFTR transgene in the lungs of cystic fibrosis patients via aerosol delivery, marking a significant breakthrough in gene therapy and potentially offering new treatment options for this patient population.
- Clinical Development Status: All product candidates are in clinical or preclinical development and have not yet received approval from the U.S. Food and Drug Administration or other regulatory authorities, highlighting the company's cutting-edge exploration in biotechnology and potential market opportunities.
See More
4D Molecular Therapeutics Q1 Earnings Beat Expectations
- Earnings Report: 4D Molecular Therapeutics reported a Q1 GAAP EPS of -$1.01, missing expectations by $0.07, indicating ongoing challenges in profitability.
- Revenue Surge: The company achieved $3.04 million in revenue for Q1, reflecting a staggering 30,300% year-over-year increase, surpassing market expectations by $0.45 million, suggesting a significant uptick in product demand that could lay the groundwork for future growth.
- Market Reaction: Despite the EPS miss, the robust revenue growth may bolster investor confidence in the company's future prospects, particularly in the increasingly competitive biotechnology sector.
- Industry Conference Participation: 4D Molecular Therapeutics presented at the Barclays 28th Annual Global Healthcare Conference and TD Cowen's 46th Annual Healthcare Conference, enhancing its visibility and investor relations within the industry.
See More
4D Molecular Therapeutics Grants 67,600 RSUs to New Employees
- Employee Incentive Program: On April 14, 2026, 4D Molecular Therapeutics granted 67,600 Restricted Stock Units (RSUs) to five new non-executive employees, reflecting the company's commitment to attracting talent and enhancing employee motivation.
- Equity Grant Context: The RSUs were awarded under the Company's 2025 Employment Inducement Award Plan, in compliance with Rule 5635(c)(4) of The Nasdaq Global Market, aimed at fostering a sense of belonging and increasing employee engagement through equity incentives.
- Product Development Progress: The lead product candidate, 4D-150, is currently in Phase 3 clinical trials, designed to provide multi-year sustained delivery of anti-VEGF through a single, safe intravitreal injection, significantly reducing the treatment burden associated with current methods, indicating potential market disruption.
- Future Outlook: The second product candidate, 4D-710, is the first known genetic medicine to successfully deliver and express the CFTR transgene in the lungs of cystic fibrosis patients, showcasing the company's innovative potential in gene therapy and offering new treatment options for patients.
See More
4D Molecular Therapeutics Reports 2025 Financial Highlights
- Revenue Growth: In 2025, 4D Molecular Therapeutics reported collaboration and license revenue of $85 million, primarily driven by an upfront payment from its strategic partnership with Otsuka Pharmaceutical, indicating positive commercial progress.
- Narrowed Net Loss: The company recorded a net loss of $140 million for 2025, an improvement from $161 million in 2024, reflecting enhanced operational efficiency despite increased R&D spending.
- Clinical Trial Advancements: The 4FRONT-1 Phase 3 trial for 4D-150 in wet age-related macular degeneration (AMD) completed enrollment ahead of schedule, with topline data expected in the first half of 2027, marking rapid progress in critical therapeutic areas.
- Financial Stability: As of December 31, 2025, the company had $514 million in cash, cash equivalents, and marketable securities, bolstered by $118 million in financing, ensuring a cash runway extending into the second half of 2028.
See More
